PreveCeutical Medical (TSE:PREV) has released an update.
PreveCeutical Medical Inc. has entered a strategic agreement to sell its intellectual property assets to BioGene Therapeutics, enhancing its Dual Gene Therapy program. The deal, valued at over $1.3 million, includes a cash payment and shares, with a portion of these shares to be distributed to PreveCeutical’s shareholders.
For further insights into TSE:PREV stock, check out TipRanks’ Stock Analysis page.
